(PCR) PCC Rokita - Ratings and Ratios
Exchange: WAR • Country: Poland • Currency: PLN • Type: Common Stock • ISIN: PLPCCRK00076
PCR EPS (Earnings per Share)
PCR Revenue
PCR: Basic Chemicals, Insulation, Cleaning, Personal, Specialty
PCC Rokita SA is a leading chemical manufacturing company with a diverse product portfolio catering to various industries, including construction, personal care, and pharmaceuticals. The companys extensive range of products includes chlorine and alkali, polyurethane insulation systems, household chemicals, and specialty products like anionic surfactants and polyols.
The companys products are used in a wide range of applications, from coatings and adhesives to lubricants and metalworking fluids. PCC Rokita SAs brands, such as Crossin, Flo, and ROKO Professional, are recognized in the industry, and the company provides logistics and transport services to support its customers. As a subsidiary of PCC SE, PCC Rokita SA leverages its parent companys resources and expertise to drive growth and innovation.
Analyzing the companys technical data, the stocks current price is 69.10 PLN, with a 20-day SMA of 71.76 PLN and a 50-day SMA of 71.42 PLN, indicating a potential downward trend. The ATR is 1.35, representing a 1.95% daily volatility. The stocks 52-week high and low are 85.80 PLN and 62.58 PLN, respectively. Based on this data, a possible short-term trading strategy could be to wait for a breakout above the 71.76 PLN level or a decline to the 62.58 PLN support level.
From a fundamental perspective, PCC Rokita SAs market capitalization is approximately 1425.47M PLN, with a P/E ratio of 10.96, indicating a relatively undervalued stock. The companys RoE is 1.66, suggesting room for improvement in terms of profitability. Given the current P/E ratio and the companys position in the commodity chemicals industry, a forecast for the stocks price could be around 75-80 PLN in the next 6-12 months, assuming a moderate improvement in the companys profitability and a stable market environment. However, this forecast is contingent on various factors, including market trends, industry developments, and the companys ability to execute its business strategy.
Additional Sources for PCR Stock
PCR Stock Overview
Market Cap in USD | 368m |
Sector | Basic Materials |
Industry | Chemicals |
GiC Sub-Industry | Commodity Chemicals |
IPO / Inception |
PCR Stock Ratings
Growth Rating | 46.9 |
Fundamental | 59.8 |
Dividend Rating | 76.3 |
Rel. Strength | -19.8 |
Analysts | - |
Fair Price Momentum | 74.80 PLN |
Fair Price DCF | 215.28 PLN |
PCR Dividends
Dividend Yield 12m | 7.16% |
Yield on Cost 5y | 19.75% |
Annual Growth 5y | 14.46% |
Payout Consistency | 87.6% |
Payout Ratio | 77.4% |
PCR Growth Ratios
Growth Correlation 3m | 33.5% |
Growth Correlation 12m | -66% |
Growth Correlation 5y | 77.9% |
CAGR 5y | 21.61% |
CAGR/Max DD 5y | 0.52 |
Sharpe Ratio 12m | -0.22 |
Alpha | -26.68 |
Beta | 0.250 |
Volatility | 22.11% |
Current Volume | 4.3k |
Average Volume 20d | 1.6k |
As of June 24, 2025, the stock is trading at PLN 67.80 with a total of 4,339 shares traded.
Over the past week, the price has changed by -2.45%, over one month by -5.44%, over three months by -3.06% and over the past year by -20.80%.
Partly, yes. Based on ValueRay´s Fundamental Analyses, PCC Rokita (WAR:PCR) is currently (June 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 59.84 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PCR is around 74.80 PLN . This means that PCR is currently undervalued and has a potential upside of +10.32% (Margin of Safety).
PCC Rokita has no consensus analysts rating.
According to our own proprietary Forecast Model, PCR PCC Rokita will be worth about 80.8 in June 2026. The stock is currently trading at 67.80. This means that the stock has a potential upside of +19.14%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 88.7 | 30.9% |
Analysts Target Price | - | - |
ValueRay Target Price | 80.8 | 19.1% |